CARY, N.C.--(BUSINESS WIRE)--Biologics, an integrated oncology services company, has promoted Daniel S. Duffy to Chief Business Development Officer. In his new role, he will oversee all sales, business development and marketing efforts for the company.
“Dan has played an instrumental role in our growth since he joined the company in 2007”
“Dan has played an instrumental role in our growth since he joined the company in 2007,” said Stuart Frantz, President & CEO. “His experience coupled with his passion for delivering exceptional service to our partners and patients has helped lay the foundation for continued growth throughout the company. I’m thrilled for him to be taking on this expanded role.”
Mr. Duffy previously served as Executive Vice President & General Manager at Biologics where he was responsible for both revenue and operations management. Under his leadership, Biologics has partnered with a number of biopharma companies, and was recognized by the National Marrow Donor Program as Partner of the Year in 2011.
In addition to his healthcare experience, Dan has served in a variety of industries and held management leadership roles in operations, corporate finance, strategic planning, business development and mergers and acquisitions. He currently serves on the Board of Advisors for the Duke Eye Center and is Chairman of the Board of Directors at the North Carolina Institute on Blindness.
“I’m honored to have the opportunity to play a broader role in supporting our sales and business development teams,” said Duffy. “It’s exciting to be part of such a rapidly growing team and I look forward to continuing to provide innovative solutions that enhance patient outcomes as we continue to grow as a company and expand upon our service offerings.”
About Biologics: Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. For more information, visit www.biologicsinc.com.